EP300 and melanoma: Studies with specific p300 inhibitors have also implicated the protein as a mediator of the oncogenic properties of melanoma [28], acute myeloid leukemia (AML) [39], neuroblastoma [40], breast cancer [41], and prostate cancer [42].